Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company LFB S.A.
DescriptionPlasma-derived von Willebrand factor (VWF) concentrate
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentMarketed
Standard IndicationBleeding
Indication DetailsTreat and prevent bleeding in von Willebrand disease (VMD) patients
Regulatory Designation
PartnerSwedish Orphan Biovitrum AB

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today